NO20032831L - Pyrimidinaminer som angiogenese-modulatorer - Google Patents
Pyrimidinaminer som angiogenese-modulatorerInfo
- Publication number
- NO20032831L NO20032831L NO20032831A NO20032831A NO20032831L NO 20032831 L NO20032831 L NO 20032831L NO 20032831 A NO20032831 A NO 20032831A NO 20032831 A NO20032831 A NO 20032831A NO 20032831 L NO20032831 L NO 20032831L
- Authority
- NO
- Norway
- Prior art keywords
- pyrimidinamines
- angiogenesis modulators
- pyrimidine derivatives
- methods
- angiogenesis
- Prior art date
Links
- 239000000587 angiogenesis modulating agent Substances 0.000 title 1
- 229940076002 angiogenesis modulator Drugs 0.000 title 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical class NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 2
- 150000003230 pyrimidines Chemical class 0.000 abstract 2
- 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25752600P | 2000-12-21 | 2000-12-21 | |
US26240301P | 2001-01-16 | 2001-01-16 | |
PCT/US2001/049367 WO2002059110A1 (en) | 2000-12-21 | 2001-12-19 | Pyrimidineamines as angiogenesis modulators |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20032831D0 NO20032831D0 (no) | 2003-06-20 |
NO20032831L true NO20032831L (no) | 2003-08-15 |
NO325987B1 NO325987B1 (no) | 2008-08-25 |
Family
ID=26946028
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20032831A NO325987B1 (no) | 2000-12-21 | 2003-06-20 | Pyrimidinaminer, anvendelse derav samt farmasoytisk preparat. |
NO2010020C NO2010020I1 (no) | 2000-12-21 | 2010-11-10 | 5-{{4-[(2,3-dimetyl-2H-indazot-6-yl)(metyl)amino]pyrimidin-2-yl}amino)-2-metylbenzensulfonamid Pazopanib. |
NO2022001C NO2022001I1 (no) | 2000-12-21 | 2022-01-06 | Pazopanib |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2010020C NO2010020I1 (no) | 2000-12-21 | 2010-11-10 | 5-{{4-[(2,3-dimetyl-2H-indazot-6-yl)(metyl)amino]pyrimidin-2-yl}amino)-2-metylbenzensulfonamid Pazopanib. |
NO2022001C NO2022001I1 (no) | 2000-12-21 | 2022-01-06 | Pazopanib |
Country Status (28)
Country | Link |
---|---|
US (6) | US7105530B2 (no) |
EP (2) | EP2311825B1 (no) |
JP (1) | JP4253188B2 (no) |
KR (1) | KR100847169B1 (no) |
CN (1) | CN1307173C (no) |
AT (1) | ATE430742T1 (no) |
AU (1) | AU2002246723B2 (no) |
BE (1) | BE2010C030I2 (no) |
BR (1) | BR0116452A (no) |
CA (1) | CA2432000C (no) |
CY (2) | CY1109160T1 (no) |
CZ (1) | CZ304059B6 (no) |
DE (2) | DE60138645D1 (no) |
DK (2) | DK2311825T3 (no) |
ES (2) | ES2556946T3 (no) |
FR (1) | FR10C0037I2 (no) |
HK (2) | HK1059926A1 (no) |
HU (2) | HU230574B1 (no) |
IL (2) | IL156306A0 (no) |
LU (1) | LU91710I2 (no) |
MX (1) | MXPA03005696A (no) |
NO (3) | NO325987B1 (no) |
NZ (1) | NZ526542A (no) |
PL (1) | PL214667B1 (no) |
PT (2) | PT1343782E (no) |
SI (2) | SI2311825T1 (no) |
WO (1) | WO2002059110A1 (no) |
ZA (1) | ZA200304482B (no) |
Families Citing this family (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2400447C (en) * | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
MXPA03005696A (es) * | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
US7153871B2 (en) | 2001-01-22 | 2006-12-26 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
US7205320B2 (en) | 2001-01-22 | 2007-04-17 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
JP4510442B2 (ja) * | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | TNF−α発現のN−ヘテロ環インヒビター |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
CA2463989C (en) * | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
HUP0402245A3 (en) * | 2001-11-01 | 2010-03-29 | Janssen Pharmaceutica Nv | Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US7338959B2 (en) | 2002-03-01 | 2008-03-04 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
CN1688553A (zh) * | 2002-06-17 | 2005-10-26 | 史密丝克莱恩比彻姆公司 | 化学方法 |
CN101423497A (zh) * | 2002-07-19 | 2009-05-06 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物 |
AU2003256616B2 (en) | 2002-07-19 | 2009-08-27 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs |
CN1678321A (zh) * | 2002-07-29 | 2005-10-05 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
JP2006503081A (ja) * | 2002-10-10 | 2006-01-26 | スミスクライン ビーチャム コーポレーション | 化学化合物 |
WO2004046113A2 (en) | 2002-11-19 | 2004-06-03 | Memory Pharmaceuticals Corporation | Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
MXPA06002608A (es) | 2002-12-20 | 2007-01-23 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
US20040167132A1 (en) * | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associted with an Edg-2 receptor |
DE602004021472D1 (en) | 2003-02-20 | 2009-07-23 | Smithkline Beecham Corp | Pyrimiidinverbindungen |
NZ544797A (en) | 2003-07-18 | 2011-04-29 | Amgen Fremont Inc | Specific antibodies that bind HGF and neutralise binding of HGF to met |
US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
JP4741491B2 (ja) | 2003-08-07 | 2011-08-03 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 抗増殖剤としての2,4−ピリミジンジアミン化合物および使用 |
JP2007510671A (ja) * | 2003-11-06 | 2007-04-26 | セルジーン・コーポレーション | アスベスト関連疾患および障害の治療および管理のための、jnk阻害剤の使用方法およびそれを含む組成物 |
WO2005105094A2 (en) * | 2004-04-16 | 2005-11-10 | Smithkline Beecham Corporation | Cancer treatment method |
EP1751142A1 (en) | 2004-05-14 | 2007-02-14 | Pfizer Products Incorporated | Pyrimidines derivatives for the treatment of abnormal cell growth |
EP1756090A1 (en) | 2004-05-14 | 2007-02-28 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
CA2564199A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2005118544A2 (en) * | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
WO2006020564A1 (en) * | 2004-08-09 | 2006-02-23 | Smithkline Beecham Corporation | Pyrimidin derivatives for the treatment of multiple myeloma |
US7799915B2 (en) * | 2004-10-13 | 2010-09-21 | Wyeth Llc | Anilino-pyrimidine analogs |
GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
CN100516049C (zh) | 2004-11-16 | 2009-07-22 | 永信药品工业股份有限公司 | 抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成 |
DK1814878T3 (da) | 2004-11-24 | 2012-05-07 | Rigel Pharmaceuticals Inc | Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf |
US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
DK1856135T3 (da) | 2005-01-19 | 2010-04-12 | Rigel Pharmaceuticals Inc | Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
WO2006129100A1 (en) * | 2005-06-03 | 2006-12-07 | Glaxo Group Limited | Novel compounds |
NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP1940841B9 (fr) | 2005-10-07 | 2017-04-19 | Guerbet | Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
WO2007064752A2 (en) * | 2005-11-29 | 2007-06-07 | Smithkline Beecham Corporation | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema |
PL1954281T3 (pl) | 2005-11-29 | 2011-07-29 | Novartis Ag | Sposób leczenia raka |
US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
TW200736232A (en) * | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
US7989631B2 (en) | 2006-02-10 | 2011-08-02 | Amgen Inc. | Hydrate forms of AMG706 |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2007143483A2 (en) * | 2006-06-01 | 2007-12-13 | Smithkline Beecham Corporation | Combination of pazopanib and lapatinib for treating cancer |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
EP2089369B1 (en) | 2006-10-19 | 2011-02-02 | Rigel Pharmaceuticals, Inc. | 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases |
EP2125781A2 (en) | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
ES2449482T3 (es) | 2007-01-09 | 2014-03-19 | Amgen Inc. | Derivados de bis-aril-amida útiles para el tratamiento de cáncer |
FR2911604B1 (fr) | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
JP2010519204A (ja) | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | 窒素含有複素環ケトン類およびそれらのc−Met阻害薬としての使用 |
WO2008128231A1 (en) * | 2007-04-16 | 2008-10-23 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
SI2188313T1 (en) | 2007-08-21 | 2018-04-30 | Amgen, Inc. | HUMAN C-FMS ANTIGEN TRANSFER PROTEIN |
EP2058307A1 (en) * | 2007-11-12 | 2009-05-13 | Cellzome Ag | Methods for the identification of JAK kinase interacting molecules and for the purification of JAK kinases |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
KR20170051521A (ko) | 2008-04-16 | 2017-05-11 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
ES2546502T3 (es) | 2008-04-16 | 2015-09-24 | Portola Pharmaceuticals, Inc. | 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas |
AU2009238590A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
MX2010012703A (es) | 2008-05-21 | 2010-12-21 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
WO2010003084A2 (en) * | 2008-07-02 | 2010-01-07 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
WO2010036796A1 (en) * | 2008-09-26 | 2010-04-01 | Concert Pharmaceuticals, Inc. | Pyridineamine derivatives |
FR2942227B1 (fr) | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
US20120232102A1 (en) | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
JP2013508396A (ja) * | 2009-10-23 | 2013-03-07 | グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド | 組成物および方法 |
WO2011058179A1 (en) | 2009-11-16 | 2011-05-19 | Ratiopharm Gmbh | 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide |
WO2011069053A1 (en) | 2009-12-04 | 2011-06-09 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl |
TW201201808A (en) * | 2010-01-06 | 2012-01-16 | Glaxo Wellcome Mfg Pte Ltd | Treatment method |
WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
BR112012024380A2 (pt) | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | compostos químicos |
AU2011254550B2 (en) | 2010-05-21 | 2013-11-07 | Noviga Research Ab | Novel pyrimidine derivatives |
JP2013526613A (ja) * | 2010-05-26 | 2013-06-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 組合せ |
JP5713367B2 (ja) | 2010-06-04 | 2015-05-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Lrrk2モジュレーターとしてのアミノピリミジン誘導体 |
WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
JP5903433B2 (ja) | 2010-08-26 | 2016-04-13 | ノバルティス アーゲー | 癌の治療に有用なvegfr阻害剤およびmek阻害剤の医薬的組み合わせ |
WO2012036919A2 (en) | 2010-09-14 | 2012-03-22 | Glaxosmithkline Llc | Combination of braf and vegf inhibitors |
EP2627179A4 (en) * | 2010-10-14 | 2014-04-02 | Ariad Pharma Inc | METHODS OF INHIBITING CELL PROLIFERATION IN EGFR-INDUCED CANCERS |
EP2635556B1 (en) | 2010-11-01 | 2017-06-21 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
WO2012061415A1 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
EP2975027A1 (en) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
CA3017869C (en) | 2010-11-10 | 2021-07-27 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
AU2011329656B2 (en) | 2010-11-19 | 2017-01-05 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
WO2012073254A1 (en) | 2010-11-29 | 2012-06-07 | Hetero Research Foundation | A process for the preparation of pazopanib using novel intermediate |
CN102060848B (zh) * | 2010-12-09 | 2013-09-18 | 天津药物研究院 | 芳香胺取代的嘧啶衍生物的制备及用途 |
CN102093339B (zh) * | 2010-12-09 | 2013-06-12 | 天津药物研究院 | 一类嘧啶衍生物的制备及用途 |
CN102093340B (zh) * | 2010-12-09 | 2013-07-17 | 天津药物研究院 | 2-甲基吲唑衍生物的制备及用途 |
US8709420B2 (en) | 2010-12-17 | 2014-04-29 | Glaxosmithkline Intellectual Property Limited | Pharmaceutical combination of pazopanib and topotecan to treat neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human |
FR2968999B1 (fr) | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
JP2014504638A (ja) | 2011-02-01 | 2014-02-24 | グラクソスミスクライン インテレクチュアル プロパティ リミテッド | 組合せ |
WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
JP5886411B2 (ja) | 2011-03-24 | 2016-03-16 | ノビガ・リサーチ・エービーNoviga Research AB | 新規のピリミジン誘導体 |
CN103476759B (zh) * | 2011-04-19 | 2016-03-16 | 拜耳知识产权有限责任公司 | 取代的4-芳基-n-苯基-1,3,5-三嗪-2-胺 |
AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
TW201636330A (zh) * | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
WO2013037894A1 (en) * | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
FR2980364B1 (fr) | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
CA2852912A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Intellectual Property Limited | Pazopanib formulation |
MX363551B (es) | 2011-11-23 | 2019-03-27 | Portola Pharmaceuticals Inc Star | Compuestos derivados de pirazina como inhibidores de cinasa. |
CN103159742B (zh) * | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用 |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
CN103373989B (zh) * | 2012-04-28 | 2016-04-13 | 上海医药工业研究院 | 盐酸帕唑帕尼的中间体的制备方法 |
JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
EP2903970A4 (en) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS |
JP6277195B2 (ja) | 2012-10-18 | 2018-02-07 | バイエル ファーマ アクチエンゲゼルシャフト | スルホン基を含んでいる5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体 |
CA2888383A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group |
US9650340B2 (en) | 2012-11-15 | 2017-05-16 | Bayer Pharma Aktiengesellschaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
CN103864764A (zh) * | 2012-12-11 | 2014-06-18 | 齐鲁制药有限公司 | 吲唑取代的嘧啶胺衍生物、其制备方法和用途 |
WO2014097152A1 (en) | 2012-12-17 | 2014-06-26 | Ranbaxy Laboratories Limited | Process for the preparation of pazopanib or salts thereof |
EP2935250B1 (en) * | 2012-12-17 | 2018-03-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of pazopanib or salts thereof |
CN103910716A (zh) * | 2013-01-07 | 2014-07-09 | 华东理工大学 | 2,4-二取代-环烷基[d]嘧啶类化合物及其用途 |
KR20150103735A (ko) | 2013-01-09 | 2015-09-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 조합물 |
FR3001154B1 (fr) | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN103214467B (zh) * | 2013-04-26 | 2015-09-30 | 中国人民解放军军事医学科学院微生物流行病研究所 | 5-[[4-[(2,3-二甲基-2h-吲唑-6-基)甲氨基]-2嘧啶基]氨基]-2-甲基-苯磺酰胺衍生物及其制备方法与应用 |
CA2917096C (en) | 2013-07-04 | 2021-05-18 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
US11136625B2 (en) | 2013-08-28 | 2021-10-05 | Crown Bioscience, Inc. (Taicang) | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
WO2015068175A2 (en) | 2013-11-05 | 2015-05-14 | Laurus Labs Private Limited | An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof |
CN103739550B (zh) * | 2014-01-02 | 2016-06-01 | 中国药科大学 | 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用 |
CN104829542B (zh) * | 2014-02-10 | 2018-02-02 | 中国科学院上海药物研究所 | 苯胺嘧啶类化合物、其制备方法和医药用途 |
WO2015136463A1 (en) | 2014-03-11 | 2015-09-17 | Glaxosmithkline Intellectual Property (No.2) Limited | Chemical compounds acting as perk inhibitors |
WO2015136028A1 (en) | 2014-03-13 | 2015-09-17 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
CA2944251C (en) | 2014-04-01 | 2022-10-18 | Bayer Pharma Aktiengesellschaft | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group |
AU2015243585B2 (en) | 2014-04-11 | 2019-08-01 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic compounds |
WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
WO2016055935A1 (en) | 2014-10-06 | 2016-04-14 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist |
US9902716B2 (en) | 2014-10-16 | 2018-02-27 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group |
US9884849B2 (en) | 2014-10-16 | 2018-02-06 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group |
AU2016205311B2 (en) | 2015-01-08 | 2022-02-17 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
EP3246046A4 (en) | 2015-01-13 | 2018-12-05 | Kyoto University | Agent for preventing and/or treating amyotrophic lateral sclerosis |
KR101705980B1 (ko) * | 2015-06-12 | 2017-02-13 | 중앙대학교 산학협력단 | 신규 파조파닙 유도체 및 이를 함유하는 약학조성물 |
CN105237523B (zh) * | 2015-10-08 | 2018-06-01 | 深圳市博圣康生物科技有限公司 | 嘧啶衍生物及其制备方法、用途 |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
EP3228630A1 (en) | 2016-04-07 | 2017-10-11 | IMBA-Institut für Molekulare Biotechnologie GmbH | Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer |
RU2018145734A (ru) | 2016-06-08 | 2020-07-14 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Химические соединения в качестве ингибиторов atf4 пути |
JP2019521109A (ja) | 2016-06-08 | 2019-07-25 | グラクソスミスクライン、インテレクチュアル、プロパテ | 化学化合物 |
JP2019521166A (ja) | 2016-07-20 | 2019-07-25 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Perk阻害剤としてのイソキノリン誘導体 |
CN110225983A (zh) | 2016-12-01 | 2019-09-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 治疗癌症的方法 |
RS62456B1 (sr) | 2016-12-22 | 2021-11-30 | Amgen Inc | Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva |
WO2018148533A1 (en) | 2017-02-09 | 2018-08-16 | Georgetown University | Compositions and methods for treating lysosomal storage disorders |
WO2018177899A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
EP3601236A1 (en) | 2017-03-28 | 2020-02-05 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
JP7108018B2 (ja) | 2017-04-17 | 2022-07-27 | イエール ユニバーシティ | 急性肺傷害を処置または予防する化合物、組成物および方法 |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
JP2020525512A (ja) | 2017-07-03 | 2020-08-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 癌および他の疾患を処置するためのATF4阻害剤としての2−(4−クロロフェノキシ)−N−((1−(2−(4−クロロフェノキシ)エチンアゼチジン(ethynazetidin)−3−イル)メチル)アセトアミド誘導体および関連化合物 |
JP2020525513A (ja) | 2017-07-03 | 2020-08-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 癌および他の疾患を治療するためのatf4阻害剤としてのn−(3−(2−(4−クロロフェノキシ)アセトアミドビシクロ[1.1.1]ペンタン−1−イル)−2−シクロブタン−1−カルボキサミド誘導体および関連化合物 |
WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
CN107619407B (zh) * | 2017-08-10 | 2019-05-24 | 山东大学 | 基于帕唑帕尼结构的hdac和vegfr双靶点抑制剂及其制备方法和应用 |
UY37866A (es) | 2017-09-07 | 2019-03-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp. |
CA3075046A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
CA3090843A1 (en) | 2018-02-13 | 2019-08-22 | Bayer Aktiengesellschaft | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
WO2019053500A1 (en) | 2018-04-17 | 2019-03-21 | Alvogen Malta Operations (Row) Ltd | PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE FORM CONTAINING PAZOPANIB AND PROCESS FOR PREPARING THE SAME |
MA52496A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
JP7360396B2 (ja) | 2018-06-01 | 2023-10-12 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及び同一物の使用方法 |
JP7357644B2 (ja) | 2018-06-11 | 2023-10-06 | アムジエン・インコーポレーテツド | がんを処置するためのkras g12c阻害剤 |
WO2020050890A2 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
TWI770624B (zh) | 2018-06-15 | 2022-07-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途 |
WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
CA3105942A1 (en) | 2018-07-09 | 2020-01-16 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
WO2020106640A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
EP3886987B1 (en) | 2018-11-30 | 2023-11-15 | GlaxoSmithKline Intellectual Property Development Limited | Compounds useful in hiv therapy |
WO2020132649A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
TWI844602B (zh) | 2018-12-20 | 2024-06-11 | 美商安進公司 | Kif18a抑制劑 |
CA3123042A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
EP3898592A1 (en) | 2018-12-20 | 2021-10-27 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
CN113195000A (zh) | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
AU2020232616A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
MX2021014126A (es) | 2019-05-21 | 2022-01-04 | Amgen Inc | Formas en estado solido. |
WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
JP2022542967A (ja) | 2019-08-02 | 2022-10-07 | アムジエン・インコーポレーテツド | Kif18a阻害剤 |
JP2022542394A (ja) | 2019-08-02 | 2022-10-03 | アムジエン・インコーポレーテツド | Kif18a阻害剤として有用なヘテロアリールアミド |
MX2022001296A (es) | 2019-08-02 | 2022-02-22 | Amgen Inc | Inhibidores de kif18a. |
AU2020325115A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | Pyridine derivatives as KIF18A inhibitors |
CN110746402B (zh) * | 2019-09-21 | 2021-01-15 | 温州医科大学 | 一种2-n-芳基-4-n-芳基-5-氟嘧啶类化合物及其制备方法和应用 |
MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
CR20220240A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
TW202132314A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras抑制劑 |
TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras抑制劑 |
CN114901662A (zh) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
US20230192682A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
BR112022009390A2 (pt) | 2019-11-14 | 2022-08-09 | Amgen Inc | Síntese melhorada de composto inibidor de kras g12c |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
IL294484A (en) | 2020-01-07 | 2022-09-01 | Revolution Medicines Inc | Dosage for shp2 inhibitor and methods for treating cancer |
EP4149475A1 (en) | 2020-05-22 | 2023-03-22 | QX Therapeutics Inc. | Compositions and methods for treating lung injuries associated with viral infections |
BR112022025550A2 (pt) | 2020-06-18 | 2023-03-07 | Revolution Medicines Inc | Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras |
WO2022040446A1 (en) | 2020-08-19 | 2022-02-24 | Nanocopoeia, Llc | Amorphous pazopanib particles and pharmaceutical compositions thereof |
CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
TW202227460A (zh) | 2020-09-15 | 2022-07-16 | 美商銳新醫藥公司 | Ras抑制劑 |
JP2024501280A (ja) | 2020-12-22 | 2024-01-11 | キル・レガー・セラピューティクス・インコーポレーテッド | Sos1阻害剤およびその使用 |
CR20230570A (es) | 2021-05-05 | 2024-01-22 | Revolution Medicines Inc | Inhibidores de ras |
TW202309053A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ras抑制劑 |
JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
IL312506A (en) | 2021-11-08 | 2024-07-01 | Progentos Therapeutics Inc | Platelet-based alpha inhibitors and their uses |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
AR129423A1 (es) | 2022-05-27 | 2024-08-21 | Viiv Healthcare Co | Compuestos útiles en la terapia contra el hiv |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0002341B1 (en) | 1977-11-28 | 1982-01-20 | Barry Boettcher | Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes |
ES2143992T3 (es) | 1991-11-25 | 2000-06-01 | Pfizer | Derivados de 5-(hetero- o carbociclilamino)-indol, su preparacion y uso como 5-ht1 agonistas. |
EP0775120B1 (en) | 1994-08-13 | 2003-06-04 | Yuhan Corporation | Novel pyrimidine derivatives and processes for the preparation thereof |
US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
PL194689B1 (pl) | 1996-02-13 | 2007-06-29 | Astrazeneca Uk Ltd | Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania |
NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
DE19610799C1 (de) | 1996-03-19 | 1997-09-04 | Siemens Ag | Zündeinrichtung zum Auslösen eines Rückhaltemittels in einem Kraftfahrzeug |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
US6294532B1 (en) | 1997-08-22 | 2001-09-25 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
WO1999016755A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
HU230522B1 (hu) | 1998-03-27 | 2016-10-28 | Janssen Pharmaceutica N.V | HIV-gátló pirimidinszármazékok |
EP1086494A4 (en) | 1998-05-15 | 2006-09-20 | Glaxo Group Ltd | IR Thermography |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
JP2002520324A (ja) | 1998-07-10 | 2002-07-09 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成インヒビター |
US6022307A (en) | 1998-07-14 | 2000-02-08 | American Cyanamid Company | Substituted dibenzothiophenes having antiangiogenic activity |
JP2002523497A (ja) | 1998-08-29 | 2002-07-30 | アストラゼネカ・アクチエボラーグ | ピリミジン化合物 |
EP1107958B1 (en) | 1998-08-29 | 2006-08-16 | AstraZeneca AB | Pyrimidine compounds |
CA2341409A1 (en) | 1998-08-31 | 2000-03-09 | Merck And Co., Inc. | Novel angiogenesis inhibitors |
US6316603B1 (en) | 1998-09-08 | 2001-11-13 | Agouron Pharmaceuticals, Inc. | Modifications of the VEGF receptor-2 protein and methods of use |
PT1119567E (pt) | 1998-10-08 | 2005-08-31 | Astrazeneca Ab | Derivados de quinazolina |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
CA2359680A1 (en) | 1999-01-22 | 2000-07-27 | David M. Armistead | Kinase inhibitors |
PL205557B1 (pl) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
WO2000052470A1 (fr) | 1999-03-04 | 2000-09-08 | Kyowa Hakko Kogyo Co., Ltd. | Moyen de diagnostic et de traitement de la leucemie |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
CO5170501A1 (es) | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
CO5170498A1 (es) | 1999-05-28 | 2002-06-27 | Abbott Lab | Biaril sulfonamidas son utiles como inhibidores de proliferacion celular |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
WO2001000213A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
BR0013899A (pt) | 1999-09-10 | 2003-07-08 | Merck & Co Inc | Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral |
ES2306671T3 (es) * | 1999-10-07 | 2008-11-16 | Amgen Inc. | Inhibidores de triazina quinasa. |
PT1244650E (pt) | 1999-11-29 | 2003-11-28 | Aventis Pharma Sa | Derivados arilaminas e sua aplicacao como agentes anti-telomerase |
ATE449764T1 (de) | 1999-12-28 | 2009-12-15 | Pharmacopeia Inc | Cytokine, insbesondere tnf-alpha, hemmer |
CA2400447C (en) * | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
WO2001074296A2 (en) | 2000-03-31 | 2001-10-11 | Imclone Systems Incorporated | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
MXPA03005696A (es) | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
-
2001
- 2001-12-19 MX MXPA03005696A patent/MXPA03005696A/es active IP Right Grant
- 2001-12-19 DE DE60138645T patent/DE60138645D1/de not_active Expired - Lifetime
- 2001-12-19 BR BR0116452-0A patent/BR0116452A/pt active Search and Examination
- 2001-12-19 IL IL15630601A patent/IL156306A0/xx unknown
- 2001-12-19 PL PL363243A patent/PL214667B1/pl unknown
- 2001-12-19 PT PT01994315T patent/PT1343782E/pt unknown
- 2001-12-19 PT PT91591388T patent/PT2311825E/pt unknown
- 2001-12-19 WO PCT/US2001/049367 patent/WO2002059110A1/en active IP Right Grant
- 2001-12-19 DK DK09159138.8T patent/DK2311825T3/en active
- 2001-12-19 ES ES09159138.8T patent/ES2556946T3/es not_active Expired - Lifetime
- 2001-12-19 DK DK01994315T patent/DK1343782T3/da active
- 2001-12-19 CN CNB018227503A patent/CN1307173C/zh not_active Expired - Lifetime
- 2001-12-19 EP EP09159138.8A patent/EP2311825B1/en not_active Expired - Lifetime
- 2001-12-19 HU HUP0400691A patent/HU230574B1/hu active Protection Beyond IP Right Term
- 2001-12-19 SI SI200131047T patent/SI2311825T1/sl unknown
- 2001-12-19 CZ CZ20031748A patent/CZ304059B6/cs not_active IP Right Cessation
- 2001-12-19 ES ES01994315T patent/ES2324981T3/es not_active Expired - Lifetime
- 2001-12-19 NZ NZ526542A patent/NZ526542A/en not_active IP Right Cessation
- 2001-12-19 JP JP2002559412A patent/JP4253188B2/ja not_active Expired - Lifetime
- 2001-12-19 CA CA2432000A patent/CA2432000C/en not_active Expired - Lifetime
- 2001-12-19 EP EP01994315A patent/EP1343782B1/en not_active Expired - Lifetime
- 2001-12-19 AU AU2002246723A patent/AU2002246723B2/en active Active
- 2001-12-19 DE DE122010000038C patent/DE122010000038I1/de active Pending
- 2001-12-19 AT AT01994315T patent/ATE430742T1/de active
- 2001-12-19 US US10/451,305 patent/US7105530B2/en not_active Expired - Lifetime
- 2001-12-19 SI SI200130922T patent/SI1343782T1/sl unknown
- 2001-12-19 KR KR1020037008349A patent/KR100847169B1/ko active IP Right Review Request
-
2003
- 2003-06-04 IL IL156306A patent/IL156306A/en active Protection Beyond IP Right Term
- 2003-06-09 ZA ZA2003/04482A patent/ZA200304482B/en unknown
- 2003-06-20 NO NO20032831A patent/NO325987B1/no active Protection Beyond IP Right Term
-
2004
- 2004-02-24 HK HK04101322.3A patent/HK1059926A1/xx not_active IP Right Cessation
-
2006
- 2006-05-15 US US11/383,229 patent/US7262203B2/en not_active Expired - Lifetime
-
2007
- 2007-07-30 US US11/830,608 patent/US8114885B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,024 patent/US7858626B2/en not_active Expired - Fee Related
-
2009
- 2009-06-18 CY CY20091100644T patent/CY1109160T1/el unknown
- 2009-10-30 US US12/609,398 patent/US20100105712A1/en not_active Abandoned
-
2010
- 2010-07-21 LU LU91710C patent/LU91710I2/fr unknown
- 2010-07-29 CY CY2010014C patent/CY2010014I2/el unknown
- 2010-08-05 BE BE2010C030C patent/BE2010C030I2/fr unknown
- 2010-08-17 FR FR10C0037C patent/FR10C0037I2/fr active Active
- 2010-11-10 NO NO2010020C patent/NO2010020I1/no not_active IP Right Cessation
-
2011
- 2011-04-26 HK HK11104135.5A patent/HK1149930A1/xx not_active IP Right Cessation
-
2012
- 2012-07-10 US US13/545,029 patent/US20120277258A1/en not_active Abandoned
-
2017
- 2017-01-11 HU HUS1700003C patent/HUS1700003I1/hu unknown
-
2022
- 2022-01-06 NO NO2022001C patent/NO2022001I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20032831L (no) | Pyrimidinaminer som angiogenese-modulatorer | |
WO2003106416A3 (en) | CHEMICAL PROCESS | |
DE60228103D1 (de) | Chemische verbindungen | |
NO20030374L (no) | Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter | |
CY1108067T1 (el) | Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης | |
MEP46108A (en) | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | |
WO2003051886A8 (en) | Pyrazolopyridazine derivatives | |
DK1083903T3 (da) | Brobundne indenopyrrolocarbazoler | |
WO2004096233A3 (en) | Nucleoside phosphonate conjugates | |
ATE281455T1 (de) | Oxindolderivate | |
DE60228295D1 (de) | Chemische verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: VOTRIENT-PAZOPANIB; NAT. REG. NO/DATE: EU/1/10/628/001-004/N 20100628; FIRST REG. NO/DATE: EU/1/10/628/001-004 20100614 Spc suppl protection certif: 2010020 Filing date: 20101110 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: VOTRIENT-PAZOPANIB; NAT. REG. NO/DATE: EU/1/10/628/001-004/N 20100628; FIRST REG. NO/DATE: EU/1/10/628/001-004 20100614 Spc suppl protection certif: 2010020 Filing date: 20101110 Extension date: 20250614 |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: GLAXOSMITHKLINE LLC, US |
|
SPCK | Change in the validity period of an spc |
Free format text: PROTECTION PERIOD CHANGED TO: 20250616 Spc suppl protection certif: 2010020 |
|
MK1K | Patent expired | ||
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: PAZOPANIB; REG. NO/DATE: 20100628 Spc suppl protection certif: 2022001 Filing date: 20220106 |
|
SPCT | Change of name or address of the representative of a supplementary protection certificate |
Spc suppl protection certif: 2010020 Representative=s name: ZACCO NORWAY AS, POSTBOKS 488, 0213 OSLO, NORGE |